Cargando…
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents
AIMS: In this pandemic, it is essential for rheumatologists and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRDs). We wanted to assess the role of targeted synthetic or biologic disease-modifying antirheumatic drugs (ts/bDMARDs) and other variables in the...
Autores principales: | Fernandez-Gutierrez, Benjamin, Leon, Leticia, Madrid, Alfredo, Rodriguez-Rodriguez, Luis, Freites, Dalifer, Font, Judit, Mucientes, Arkaitz, Culebras, Esther, Colome, Jose Ignacio, Jover, Juan Angel, Abasolo, Lydia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869066/ https://www.ncbi.nlm.nih.gov/pubmed/33613703 http://dx.doi.org/10.1177/1759720X20962692 |
Ejemplares similares
-
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020) -
Factors associated with sepsis risk in immune-mediated inflammatory
diseases receiving tumor necrosis factor inhibitors: a nationwide
study
por: Chao, Wen-Cheng, et al.
Publicado: (2020) -
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review
por: Tsai, Y. C., et al.
Publicado: (2020) -
JAK inhibitors and infections risk: focus on herpes
zoster
por: Sunzini, Flavia, et al.
Publicado: (2020) -
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)